P L A I N L A N G U A G E S U M M A R Y What is tuberculous pleurisy and how might corticosteroids work?
Tuberculous pleurisy results from inflammation of the membrane that covers the lungs (the pleura) caused by exposure to Mycobacterium tuberculosis bacteria infecting the lungs. This results in a build up of fluid around the lung (pleural e usion) that causes pain and fever, impairs breathing, and may lead to impairment of lung function in the long term.
Some clinicians believe that corticosteroids used in combination with antituberculous drugs can speed up the recovery from TB pleurisy and help to prevent long-term complications.
What the evidence shows
We examined the available evidence up to 13 April 2016 and included six trials with 590 people, which evaluated prednisolone given with antituberculous treatment (ATT). One included trial was of high quality, while the rest had uncertainties regarding trial quality. All the included trials were in adults; one trial included only HIV-positive people, two included only HIV-negative people, and three did not report the HIV status of the participants.
Corticosteroids may reduce the time to resolution of the symptoms of TB pleurisy and the time to resolution of the pleural e usion on chest X-ray (low certainty evidence). Corticosteroids may also reduce the risk of having signs of pleural scarring on chest X-ray (pleural thickening and pleural adhesions) a er the disease has resolved (low certainty evidence). There was not enough information about lung function to be sure whether or not corticosteroids reduce the risk of lung function impairment a er TB pleurisy (very low certainty evidence).
Corticosteroids may increase the risk of adverse events leading to discontinuation of the trial drug (low certainty evidence). From one trial in people living with HIV, there was no detectable increase in HIV-related conditions with corticosteroids, although cases of Kaposi's sarcoma were only seen in the corticosteroid group and numbers of participants and events were too small to rule out an e ect of corticosteroids (very low certainty evidence).
As the risk of disability and long-term illness a er TB pleurisy is unclear, research looking at the association between TB pleurisy and lung function impairment would be useful to inform future research into corticosteroids for TB pleurisy. Cochrane Database of Systematic Reviews
B A C K G R O U N D
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis complex, and is a major cause of illness and death worldwide. In 2014 approximately 9.6 million people newly developed the disease and there were 1.5 million deaths globally (WHO 2015) . TB infects the lungs, and is transmitted by droplet spread from coughing people with active pulmonary TB, but it can also spread to other body sites and cause extrapulmonary TB (EPTB).
Description of the condition
Pleural TB is one of the most common forms of EPTB, with an incidence of 3% to 25% of people with TB (Light 2010; Sharma 2004) . The incidence is higher in high TB prevalence settings (Jeon 2014) . Immune compromise is an important risk factor for all forms of TB, and evidence suggests that pleural TB is more common in people living with HIV (Batungwanayo 1993; Frye 1997; Pozniak 1995; Saks 1992) . Pleural TB can be a manifestation of TB disease post-primary infection, or due to reactivation of latent TB (Light 2010).
Clinically, pleural TB presents as an acute illness consisting of cough, fever, chest pain, and shortness of breath (Morehead 1998), and usually a pleural e usion is demonstrated on chest X-ray. Pleural TB usually resolves without treatment of any kind, but untreated patients may experience longer duration of the acute symptoms and risk recurrence of active TB at a later point in time (Light 2010) . Pleural TB can be complicated by massive e usion leading to respiratory compromise in the short term, and pleural thickening, fibrosis, and pleural adhesions causing impaired respiratory function in the medium-to long-term.
Pleural TB is thought to be caused by a delayed type (type IV) hypersensitivity reaction following release of mycobacterial antigens into the pleural space (Rossi 1987) , as a result of rupture of a subpleural focus of TB infection in the lung (Stead 1955) . This explains the tendency towards resolution of the e usion and associated symptoms with or without treatment of the TB infection, and the fact that culture of pleural fluid is nearly always negative for M. tuberculosis. There appears to be a spectrum of disease in pleural TB in terms of the extent of the underlying lung infection, which could be important in terms of patient outcomes and the potential for corticosteroids to be e ective (Table 1) . A systematic review that includes 18 trials and 3816 participants suggests that corticosteroids probably do not improve mortality rates, sputum smear or culture conversion in people with pulmonary TB (Critchley 2014). One cohort study of people with pleural TB in Spain reported evidence of pulmonary TB infection on chest X-ray in 20% of 254 participants (Valdés 1998) . Pulmonary involvement rose to 86% in another cohort where computed tomography (CT) scanning was used (Kim 2006) . Shu 2011 demonstrated that pulmonary involvement (as defined by positive sputum culture and/or chest X-ray appearances) was an important predictor of mortality in hospitalised pleural TB patients in Korea, and was associated with a longer hospital stay.
Diagnosis of pleural TB can be challenging with traditional microscopy and culture methods being relatively insensitive when used on pleural fluid, and newer modalities such as Xpert® MTB/ RIF have similar limitations (Denkinger 2014). Histopathological examination and mycobacterial culture performed on pleural biopsy samples are regarded as more reliable tests, and yielded a diagnosis in 227/248 patients (91%) in one cohort study (Valdés 1998) .
Description of the intervention
Corticosteroids are hormones produced by the adrenal cortex which have a variety of physiological functions, including carbohydrate metabolism, protein catabolism, regulation of electrolytes, the stress response and control of inflammation. Corticosteroids induce their anti-inflammatory e ect through the regulation of gene expression in cells, leading to increased expression of genes which inhibit inflammatory pathways, and repression of genes encoding pro-inflammatory proteins (Barnes 2006) . Multiple synthetic forms of these hormones have been produced and are used in the treatment of a wide variety of inflammatory conditions. Prednisolone is a synthetic corticosteroid derived from cortisol, and prednisone is a pro-drug that is converted into the active form prednisolone by the liver. Several formulations of each drug are used for di erent conditions and diseases; in TB pleurisy patients are usually o ered them in tablet form.
Corticosteroids have been used in medicine for many decades, and have well-characterised adverse e ect profiles. Adverse e ects for medium to long-term use include hyperglycaemia, hypertension, increased risk of infection, osteoporosis, gastric ulceration and gastrointestinal bleeding, thinning of the skin, proximal myopathy, psychiatric symptoms, and development of moon face, striae and acne (Cushing's syndrome). The use of synthetic corticosteroids can induce adrenocorticoid insu iciency, and so patients receiving more than one week's treatment must have the dose slowly reduced to avoid acute adrenal insu iciency causing hypotension and hypoglycaemia which can be life-threatening (BNF 2016) .
How the intervention might work
Therapeutic options for pleural space infections include intravenous antibiotic administration, chest tube drainage, intrapleural administration of a fibrinolytic agent to dissolve fibrous adhesions, thoracotomy to remove fibrinous and infected tissue, and steroid therapy (Chapman 2004).
The theoretical basis for using corticosteroids is that they suppress the delayed type hypersensitivity inflammatory response triggered by the release of tubercular antigens into the pleural space which is believed to be responsible for tuberculous pleurisy. One corticosteroid is prednisone, which is converted in the liver into the active drug, prednisolone. Prednisolone is recommended at a daily dose of about 1 mg/kg gradually reducing a er one to two weeks, with a total treatment course sometimes being as long as three months (Lemaistre 1951; Mathur 1960; Morehead 1998; Blumberg 2003) .
Corticosteroids have anti-inflammatory properties, produced mainly via suppression of pro-inflammatory gene expression and activation of anti-inflammatory genes (Barnes 2006 Cochrane Database of Systematic Reviews therefore reduce the duration or severity of symptoms in the short term, and also reduce the risk of tissue damage leading to lung impairment in the long term.
Why it is important to do this review
Studies of adjunctive corticosteroids for the treatment of tuberculous pleural e usion show conflicting results. Nonrandomized studies in the pre-HIV era found that corticosteroids led to more rapid resolution of the e usion and reduced likelihood of residual pleural thickening and pleural adhesions (Menon 1964; Singh 1965 ). An observational study of 165 HIV-positive participants with tuberculous pleural e usion found that prednisolone was associated with decreasing rates of lymphadenopathy and cough as well as improved survival (Elliott 1992; Elliott personal communication).
In contrast, a critical appraisal of published studies demonstrated beneficial e ects of corticosteroids on acute symptoms, but it found no benefit for chronic endpoints such as fibrosis, irrespective of dose (Dooley 1997) . The authors noted that many of the studies lacked rigour and clinical correlations. The previous version of this Cochrane review (Engel 2007) , which included six trials and 633 participants, concluded that data were insu icient to support the use of corticosteroids in pleural TB.
In addition to the uncertainty about benefits of corticosteroid therapy, there is concern about potential risks. In immunocompromised patients, such as those infected with HIV, corticosteroids may further constrain the immune system leading to an increased frequency of opportunistic infections and tumours such as Kaposi's sarcoma, a vascular tumour accompanied by numerous unconnected lesions of the skin and associated with human herpes virus-8 infection (Ensoli 2001 
O B J E C T I V E S
To evaluate the e ects of adding corticosteroids to drug regimens for tuberculous pleural e usion.
M E T H O D S

Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
People diagnosed with tuberculous pleurisy by chest x-ray (as defined by trial authors) plus any of the following: pleural biopsy for histology; staining and microscopy for acid-fast bacilli, or culture of sputum, or both; pleural fluid; or pleural biopsy.
Types of interventions
Intervention
Any corticosteroid at any dose.
Control
Placebo or no adjunctive treatment.
Both treatment groups should receive the same antituberculous drug regimen.
Types of outcome measures
Short term (under six months)
• Time to resolution of clinical symptoms (as defined by the authors, including fever and pain) • Time to resolution of pleural e usion
Long term (six months or more)
• Pleural changes at the end of treatment (pleural thickening and pleural adhesions) • Change in respiratory function • Disability (as defined by authors) • Deaths from any cause
We will also report on other outcomes of resolution as defined by the author.
Adverse e ects
• Corticosteroid-associated adverse e ects • HIV-associated adverse e ects
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress) .
Electronic searches
We searched the following databases using the search terms and strategy described in Appendix 1: the Cochrane Infectious Diseases Group Specialized Register (18 November 2016); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (18 November 2016); MEDLINE (1966 to 18 November 2016 Embase (1974 to 18 November 2016 and LILACS (1982 to 18 November 2016) . We also searched Current Controlled Trials (18 November 2016) using 'tuberculosis' and 'pleur*' as search terms.
Searching other resources
We performed hand searches of the reference lists of all studies identified with the above methods. 
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Data collection and analysis
Selection of studies
The review authors screened the results of the search for potentially relevant studies. We independently applied eligibility criteria and resolved di erences in opinion through discussion. Where the abstracts were unclear or if there was any other reason for uncertainty, we obtained the full-text article before we made a decision on study eligibility, and we contacted the study authors where necessary. We consulted translators when abstracts were unavailable in English. We assessed the full-text articles of potentially relevant studies and included trials that met the inclusion criteria. We listed studies that did not meet our inclusion criteria and stated the reason for exclusion in a 'Characteristics of excluded studies' table. We constructed a PRISMA diagram to illustrate the study selection process.
Data extraction and management
Two review authors (PD and HR) independently extracted data from the included trials on participant characteristics, diagnostic criteria, HIV status, antituberculous drug regimen, corticosteroid regimen, and outcome measures using a pre-piloted data extraction form. One review author (JY) extracted data from Bang 1997 and Lee 1999 as both trial reports were in Korean. We resolved disagreements through discussion and contacted the corresponding trial author in the case of unclear or missing data.
For dichotomous outcomes, we recorded the number of participants that experienced the event and the number of participants in each treatment group. For continuous outcomes, we extracted the arithmetic means and standard deviations for each treatment group together with the numbers of participants in each group.
Assessment of risk of bias in included studies
Two review authors (PD and HR, or JY and HR) independently assessed the risk of bias for each included trial using the Cochrane 'Risk of bias' tool (Higgins 2011). We resolved any di erences of opinion through discussion with reference to the trial reports, and through discussion with the Cochrane Infectious Diseases Group Co-ordinating Editor, Paul Garner. We followed the guidance to assess whether adequate steps had been taken to reduce the risk of bias across six domains.
• Random sequence generation • Allocation concealment • Blinding of participants and personnel • Blinding of outcome assessors • Incomplete outcome data • Selective reporting • Other bias When assessing risk of bias related to blinding (performance bias or detection bias), we planned to consider the implications of blinding separately for each outcome, as appropriate.
For assessment of bias related to incomplete outcome data (attrition bias), we used the following criteria to assess risk of bias.
• Low risk: less than 5% of participants were lost to follow-up • Unclear risk: between 5 and 10% of participants were lost to follow-up • High risk: more than 10% of participants were lost to follow-up For selective reporting (reporting bias), we used the following criteria to determine the risk of bias.
• Low risk: the trial authors stated in the introduction or method sections the outcomes they would look at, and they reported all of them in the results section • Unclear risk: the trial authors did not state in the introduction or method sections the outcomes they would look at • High risk: the trial authors stated the outcomes they would look at but they did not report all of them in the results section
We categorized these judgments as either at low, high, or unclear risk of bias. We attempted to contact the trial authors for clarification if any details were unclear; where our judgement is recorded as 'unclear' we were unable to amend our judgement a er we contacted the trial authors. The results of the 'Risk of bias' assessment are displayed in the 'Characteristics of included studies' tables.
Measures of treatment e ect
For dichotomous outcomes, we used relative risk as the measure of treatment e ect for analysis. For continuous outcomes we planned to use mean di erence, but this was not necessary in the final review dra .
Unit of analysis issues
There were no cluster-RCTs amongst the included trials, so individual participants were the unit of analysis.
Dealing with missing data
The primary analysis was an intention-to-treat analysis where all participants randomized to treatment were included in the denominator, where possible. This analysis assumes that all losses to follow-up have good outcomes. We planned to explore the e ect of losses to follow-up on the overall e ect estimates by performing sensitivity analyses.
Assessment of heterogeneity
We assessed heterogeneity by visually inspecting the forest plots to determine closeness of point estimates with each other and overlap of confidence intervals (CIs). We used the Chi test with a P value of 0.10 to indicate statistical significance, and the I statistic to assess heterogeneity with a value of 50% taken to indicate statistical heterogeneity. We planned to investigate heterogeneity through the following subgroup analyses: corticosteroid dose, HIV status, and methodological quality.
Assessment of reporting biases
We planned to look for publication bias by constructing a funnel plot, but there were too few studies to do this.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 5) (Review Manager 5). For outcomes where it was possible to combine data and clinical heterogeneity was low, we decided to perform a metaanalysis. We used risk ratios (RR) with 95% CIs and the fixed-e ect Cochrane Database of Systematic Reviews model. For outcomes where it was not possible to combine data, we described the results in tables. We summarized the adverse event data in tables and performed meta-analysis for adverse events leading to discontinuation of the trial drug, and HIV-associated adverse events.
Subgroup analysis and investigation of heterogeneity
Where there was substantial unexplained statistical heterogeneity, we carried out subgroup analyses to investigate possible causes.
Sensitivity analysis
To explore the possible e ect of losses to follow-up, we planned to conduct a worst case scenario analysis and compare it with an available-case analysis for the outcome pleural changes at the end of treatment. There were few losses to follow-up in the included trials, and the two trials with the highest number of losses to follow-up did not state which treatment groups these participants were randomized to. Therefore we did not conduct the sensitivity analysis as planned.
Quality of the evidence
We assessed the quality of the evidence using the GRADE approach (Jüni 2001). We used GRADEpro Guideline Development Tool (GDT) so ware to construct a 'Summary of findings' table (GRADEpro GDT 2014) .
R E S U L T S
Description of studies
Results of the search
In the 2007 version of this Cochrane Review, we screened 48 studies, of which we identified 27 published trials for possible inclusion into the review. Six trials met the inclusion criteria (Engel 2007) . In this review update, the search returned one new study, which we excluded. Figure 1 shows the study selection process.
We have described the characteristics of the included studies in the 'Characteristics of included studies' tables and summarized the results in Table 2 . 
Included studies
Settings
The six trials included 633 participants, with a range of 45 to 197 per trial, and were conducted in a various countries: Taiwan (Lee 1988), Spain (Galarza 1995), South Africa (Wyser 1996), Korea (Bang 1997; Lee 1999), and Uganda (Elliott 2004). All trials were single centre trials based in large tertiary care hospitals.
Participants
All participants were adults except in one trial, Galarza 1995, which included people aged 11 years and older. All trials included participants of both sexes; overall 59% were male, with a range of 51% to 64% across trials.
One trial included only HIV-positive participants (Elliott 2004), two trials excluded HIV-positive participants (Galarza 1995; Wyser 1996) , while the other included trials did not mention the HIV status of the participants.
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All but one trial, Galarza 1995, specified the exclusion of participants with co-morbidities that may be exacerbated by the use of corticosteroids, particularly hypertension, diabetes mellitus, and peptic ulcer disease. Elliott 2004 also specified the exclusion of participants with another major HIV-related disease.
We have described the diagnostic tests performed in each included trial in Table 3 . Diagnosis of pleural TB was made on the basis of either characteristic histopathological features on pleural biopsy or positive culture or acid-fast bacilli (AFB) on smear microscopy staining from pleural fluid, biopsy or sputum in three trials (Elliott 2004; Lee 1999; Wyser 1996) . Galarza 1995 also included participants with a diagnosis of tuberculous pleurisy based on a combination of at least two of: reactive Mantoux test, lymphocytic pleural fluid, and raised adenosine deaminase activity in pleural fluid. Bang 1997 only included participants who had positive microscopy for AFB from sputum, pleural fluid, or pleural biopsy. Lee 1988 included participants with pleural biopsy "reported as pleural tuberculosis or chronic granulomatous inflammation".
Interventions
We have summarized the antituberculous therapy (ATT) regimens used in the included trials in Table 2 , and the corticosteroid regimens used in Table 4 .
Four trials compared either prednisone or prednisolone with placebo as an adjunct to an established antituberculous regimen containing at least isoniazid and rifampicin (Elliott 2004; Galarza 1995; Lee 1988; Wyser 1996) . Bang 1997 and Lee 1999 did not use any comparative treatment in the control group.
Four trials used weight-based dosing of corticosteroids; Bang 1997 started at 1.0 mg/kg twice daily, Galarza 1995 started at 1.0 mg/kg/ day, and Lee 1988 and Wyser 1996 started at 0.75 mg/kg/day. Elliott 2004 started at 50 mg/day for all participants, and Lee 1999 started at 30 mg four times daily. Lee 1988 and Wyser 1996 tapered the dose of corticosteroid according to the participant's clinical progress; the other included trials either had fixed tapering regimens or did not describe the tapering regimen.
All included trials described performing diagnostic pleural aspiration (thoracocentesis) as part of eligibility screening and diagnosis of pleural TB. Two trials also performed therapeutic thoracocentesis (Galarza 1995; Wyser 1996) . In Galarza 1995, pleural fluid was drained in all participants before discharge "until a third of the hemithorax was observed to be occupied in a standard chest radiograph". In Wyser 1996, thoracoscopy and bronchoscopy were performed in all participants under general anaesthesia at admission, and chest drains were le in situ for 48 hours following the procedure to drain remaining pleural fluid.
Outcomes
Follow-up varied from six months to 24 months. Two trials did not clearly state the length of follow-up (Bang 1997; Lee 1999).
None of the included trials reported all the outcome measures chosen for this review.
Five trials reported on resolution or improvement of clinical symptoms in some way. Bang 1997 and Wyser 1996 both used self-reported questionnaires to assess the time until symptom improvement and resolution in all participants; Wyser 1996 asked participants to grade the severity of a range of symptoms on a visual analogue scale. Lee 1988 reported the time to resolution of symptoms "including fever, chest pain and dyspnoea" for all participants, but did not specify how this was assessed. Elliott 2004 reported on improvement of anorexia, weight loss, and cough, but data for other symptoms was not reported. Galarza 1995 reported on time to resolution of fever.
Five trials reported on time to resolution of pleural e usion (Bang 1997; Elliott 2004; Galarza 1995; Lee 1988; Lee 1999) . Four trials reported the number of participants with residual pleural e usion at various time points during treatment (Bang 1997; Elliott 2004; Lee 1988; Lee 1999) . Bang 1997 and Lee 1988 also reported the mean number of days to resolution of pleural e usion. Galarza 1995 reported the mean reabsorption index for all participants over time. The trial authors calculated the reabsorption index as follows: (length of a ected hemithorax/length of healthy hemithorax) x 100. Wyser 1996 reported recurrence of pleural e usion, rather than time to resolution, as all participants had therapeutic thoracocentesis at the start of treatment.
Five trials reported on pleural changes at various time points throughout treatment and at the end of follow-up (Bang 1997; Galarza 1995; Lee 1988; Lee 1999; Wyser 1996) . Galarza 1995 and Wyser 1996 described the diagnostic criteria for pleural thickening on chest X-ray (Wyser 1996 also used high-resolution computed tomography). Three trials did not describe the criteria for classifying participants as having pleural adhesions or pleural thickening (Bang 1997; Lee 1988; Lee 1999) .
Two trials reported on respiratory function (Galarza 1995; Wyser 1996) . In Wyser 1996, spirometry and body plethysmography were performed at admission and at various points during follow-up. In Galarza 1995, spirometry was performed at the start and end of treatment. Neither trial reported the complete data for this outcome.
Disability was not reported in any of the included trials. Only one trial reported any deaths (Elliott 2004).
Elliott 2004 reported on CD4+ cell count at enrolment to the trial and at 1, 2, 6, and 18 months a er start of treatment. A subset of participants (N = 40) also had blood and pleural fluid specimens analysed for HIV viral load.
All trials reported adverse events, although there was variation in the level of detail. Elliott 2004 reported on HIV-related disease as well as corticosteroid-related adverse events.
Excluded studies
We have listed the reasons for excluding 22 studies in the 'Characteristics of excluded studies' section.
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Figure 3. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial. Allocation
All included trials were reported as randomized. Elliott 2004 explicitly stated that random numbers were computer-generated, which we considered to be low risk of bias. The other included trials did not indicate how the sequence was generated, and we assessed them as at unclear risk of bias.
One trial gave a detailed description of the method of allocation concealment and we assessed it as at low risk of bias; briefly, prednisolone and matching placebo tablets were packaged in identical sequentially numbered plastic bags labelled with the randomization code by two people unrelated to the trial (Elliott 2004). The rest did not describe the method of allocation concealment, and so we classified them as at unclear risk of bias.
Blinding
Four trials described blinding of participants and personnel and we assessed them as at low risk of bias (Elliott 2004; Galarza 1995; Lee 1988; Wyser 1996) . Bang 1997 and Lee 1999 did not mention blinding, and therefore we classified them as at unclear risk of bias. 
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Two trials specified blinding of outcome assessors and we assessed them as being at low risk of bias (Elliott 2004; Wyser 1996) . None of the other trials reported whether or not outcome assessors were blinded to treatment allocation, and so we assessed them as at unclear risk of bias.
Incomplete outcome data
Three trials did not report any losses to follow-up (Bang 1997; Galarza 1995; Lee 1999) . Bang 1997 excluded one participant in the corticosteroid group from the analysis as the trial drug had to be stopped due to epigastric pain. Elliott 2004 reported 3/197 (1.5%) participants lost to follow-up; one from the placebo group and two from the corticosteroid group. We categorised these trials as at low risk for attrition bias.
Wyser 1996 excluded 4/74 (5.4%) from the analysis; three due to noncompliance with treatment and one due to a diagnosis of oesophageal cancer during treatment. The authors do not report which groups the excluded participants were allocated to. We categorised this trial as at unclear risk of attrition bias.
Lee 1988 excluded 5/45 (11.1%) from the analysis; one due to a diagnosis of renal cell carcinoma during treatment, and four were lost to follow-up. We classified this trial as at high risk of attrition bias.
Selective reporting
Trial protocols were unavailable for all of the included trials. Five trials stated the outcomes clearly in the introduction and methods sections of the study reports, and reported all stated outcomes (Bang 1997; Galarza 1995; Lee 1988; Lee 1999; Wyser 1996) .
Elliott 2004 reported that the hypothesis of the trial was that prednisolone would improve long-term survival, and decrease HIV viral replication, but did not list the planned outcomes. We assessed this trial as at high risk of reporting bias because in the results section it implied that data on resolution of symptoms that did not demonstrate a statistically significant positive e ect of prednisolone was not reported, whereas data were reported for the outcomes of anorexia, weight, and cough where a statistically significant positive e ect was found.
Other potential sources of bias
We did not find enough trials that met the inclusion criteria for us to conduct a funnel plot to look for possible publication bias.
E ects of interventions
See: Summary of findings for the main comparison
Time to resolution of clinical symptoms
Due to the di erent units of measurement used in the trials, and insu icient reported data, it was not possible to combine the e ects in a meta-analysis for this outcome. We have presented the results from the included trials in Table 5 . Qualitatively, corticosteroids appear to be associated with more rapid resolution of symptoms, but we were unable to assess the relative e ect of corticosteroids statistically.
Time to resolution of pleural e usion
Five trials reported on time to resolution of pleural e usion (Bang 1997; Elliott 2004; Galarza 1995; Lee 1988; Lee 1999) . We combined data for the number of participants with a residual pleural e usion on chest X-ray in each treatment group from four trials. Bang 1997 , Elliott 2004 , and Lee 1988 reported data across three time points (4 weeks, 8 weeks, and 24 weeks), and Lee 1999 reported data for two time points (8 weeks and 24 weeks). Galarza 1995 presented the mean reabsorption index for each treatment group at four weeks, and so we could not use data from this trial in the meta-analysis. We have presented the results from each trial in Table 6 . Wyser 1996 reported on recurrence of pleural e usion, as all participants had drainage of their pleural e usions at admission to the trial, and reported no recurrences of pleural e usion in either group.
The initial meta-analysis, which includes data from Bang 1997 , Elliott 2004 , Lee 1988 , and Lee 1999, found substantial statistical heterogeneity at all three time points, and we conducted a subgroup analysis to explore this (Analysis 2.1; Analysis 2.2). When we excluded trials that were at high risk of bias for selection bias (randomization and allocation concealment) from the metaanalysis, the statistical heterogeneity resolved. In these two trials it is possible that the trial investigators allocated a greater proportion of participants with more severe pleural e usions to the corticosteroid group, believing that corticosteroids would be of benefit to them (Bang 1997; Lee 1999) . This would lead to bias towards the null, and a misleading summary e ects estimate. For this reason, we excluded the trials that were at high risk of selection bias from the meta-analysis.
The results showed a reduction in the risk of having residual pleural fluid on chest X-ray at all three time points in participants treated with corticosteroids: by 36% at four weeks (RR 0.64, 95% CI 0.49 to 0.84; 237 participants, 2 trials), 45% at eight weeks (RR 0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials), and 65% at 24 weeks (RR 0.35, 95% CI 0.18 to 0.66; 237 participants, 2 trials).
Pleural changes on chest X-ray at the end of treatment
Five trials reported on chest X-ray changes to the pleura at the end of treatment (Bang 1997; Galarza 1995; Lee 1988; Lee 1999; Wyser 1996) . The terms 'pleural thickening' and 'pleural adhesions' were used to describe these changes, and in some cases seemed to be used interchangeably. We found that corticosteroids may reduce the risk of having pleural changes on chest X-ray a er at least six months by 28% (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials, low certainty evidence; Analysis 1.2).
One trial, Galarza 1995, attempted to quantify the degree of pleural thickening by measuring the maximal pleural thickening in millimetres at 1, 6, and 12 months a er enrolment, and reported the mean maximal pleural thickness for each treatment group. The prednisolone group had a mean maximal pleural thickness of 1.77 mm (range 0 to 40 mm), and for the placebo group 2.23 mm (0 to 15 mm), with a P value of more than 0.05.
Wyser 1996 also performed high resolution CT scan of the chest in most participants, and found 17/32 participants in the prednisolone group and 21/35 participants in the placebo group had pleural thickening at the end of treatment using this test (P = 0.52). 
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None of the included trials looked at the extent of pleural changes on chest X-ray in terms of area of pleural change.
Change in respiratory function
Two trials with 191 participants measured improvement in respiratory function and found no di erence between the groups (Galarza 1995; Wyser 1996) . We have summarized the results in Table 7 .
In Galarza 1995, mean forced vital capacity (FVC) was 95% in both the treatment and control groups at the end of treatment; in Wyser 1996 it was 85% in the corticosteroids group and 80% in the placebo group (P = 0.65). We could not perform a meta-analysis due to insu icient reported data.
Disability
None of the included trials looked at disability or functional impairment a er treatment for TB pleurisy.
Death from any cause
Only Elliott 2004 reported any deaths, with 36/99 deaths in the prednisolone group, and 39/98 deaths in the placebo group, meaning the relative risk of death in the prednisolone group was 0.91 (95% CI 0.64 to 1.31; 197 participants, 1 trial; Analysis 1.3), which indicated that prednisolone did not confer a survival benefit. The trial authors commented that mortality rates were higher in participants with low CD4+ cell counts on enrolment to the trial.
Adverse e ects of treatment
More participants in the corticosteroid group had adverse events leading to discontinuation of the study drug (RR 2.78, 95% CI 1.11 to 6.94; 590 participants, 6 trials, low certainty evidence; Analysis 1.4).
We have summarized the results in Table 8 .
There was variation in the level of detail reported across the di erent trials, and assessment of participants to detect adverse e ects of treatment also varied.
Bang 1997 reported one participant from the corticosteroid group was withdrawn from the study due to aggravation of epigastric pain.
Lee 1988 reported one participant from the corticosteroid group developed moon-shaped face, epigastric pain, and lower limb oedema which resolved on tapering the study drug.
Wyser 1996 reported that the only adverse e ect observed was epigastric pain, which a ected 4/34 participants in the corticosteroid group and 3/36 participants in the placebo group.
Elliott 2004 reported 9/99 participants in the corticosteroid group stopped the trial drug due to hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants), or oesophageal candidiasis (one participant).
In the placebo group 2/98 participants stopped the trial drug; one participant due to hyperglycaemia and one participant due to hypertension.
Galarza 1995 reported no adverse events in either treatment group, and Lee 1999 reported no significant adverse events in the participants treated with steroids.
HIV-associated adverse events
Only Elliott 2004 included HIV-positive participants. The trial reported adverse events related to HIV, including candidiasis, herpes simplex and herpes zoster, cryptococcal meningitis, gastroenteritis, and Kaposi's sarcoma (summarized in Table 9 ). For most of these adverse events there was no di erence between the corticosteroid and placebo groups. For Kaposi's sarcoma, there was a statistically non-significant trend towards increased risk with corticosteroids: 6/99 in the corticosteroid group developed Kaposi's sarcoma compared with 0/98 in the placebo group (RR 12.87, 95% CI 0.73 to 225.40; 197 participants, 1 trial, very low certainty evidence).
D I S C U S S I O N
Summary of main results
See 'Summary of findings' table 1 (Summary of findings for the main comparison).
Six trials met the inclusion criteria; we have not included any new trials since the 2007 version of this Cochrane Review (Engel 2007) , and we did not find any trials in progress that address this question.
There was a trend towards faster resolution of symptoms, such as fever and chest pain, with corticosteroids across all included trials, but the trials reported insu icient data to produce a metaanalysis addressing time to resolution of symptoms, and there were variations across studies in terms of which symptoms were reported and who the participants were monitored and assessed.
Corticosteroids probably reduce the time to resolution of pleural e usion.
Corticosteroids may reduce risk of pleural changes on chest X-ray at the end of treatment by 28% (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials, low certainty evidence). On average, half the participants in the control group had pleural changes at the end of at least six months, giving an estimated absolute risk reduction of 14% with corticosteroids.
There was insu icient data to draw conclusions about the e ect of corticosteroids on respiratory function a er treatment, and none of the included trials reported on disability a er treatment. Only one trial reported on death (Elliott 2004), and the trial authors' analysis suggests that death was related to low CD4+ cell counts, which implied that death was related to severity of HIV disease. Corticosteroids had no e ect on all-cause mortality in this trial (RR 0.91, 95% CI 0.64 to 1.31; 197 participants, 1 trial).
Corticosteroids may increase risk of adverse events leading to discontinuation of the study drug (RR 2.78, 95% CI 1.11 to 6.94; 587 participants, 6 trials, low certainty evidence). Commonly reported adverse e ects included epigastric pain, hypertension, and hyperglycaemia.
Only one trial included HIV-positive people and reported on HIV-associated adverse events (Elliott 2004 
Overall completeness and applicability of evidence
The six trials included male and female participants, who were mostly HIV-negative adults. One trial included children over the age of 11 years (Galarza 1995), and one trial included only HIVpositive adults (Elliott 2004) . The trials reflected the fact that pleural TB is more common in adults, but HIV-positive people are underrepresented in this review, and the results of the pooled estimates may be less applicable to HIV-positive people. The included trials were all conducted in tertiary hospital settings, in a countries varying from low to high TB burden and HIV prevalence.
The method of diagnosis of pleural TB varied between the included trials (see Table 3 ), but were representative of diagnostic tests commonly available in high-and middle-income settings. Culture and histopathology are less accessible in low-income settings, where diagnosis may be based on clinical presentation and X-ray findings alone.
The antituberculous treatment (ATT) that participants received varied across the included trials, and in some trials the treatment given was significantly di erent from widely recommended firstline treatment for drug-sensitive TB (see Table 2 ). Most notably, the older trials included either two drugs (Lee 1988), or three drugs (Galarza 1995; Wyser 1996) , in their regimens rather than all four currently recommended first-line drugs in the intensive phase of treatment. Participants were given at least six months of ATT in all trials. This variation in ATT was not associated with statistically significant heterogeneity in any of our analyses. As the more recent trials used regimens that are the same or very similar to currently recommended regimens for drug-sensitive TB, it is unlikely that the variation in ATT regimens between the trials limits the applicability of the evidence.
For some outcomes, such as respiratory function and time to resolution of symptoms, incomplete reporting of data and di erences in units meant that we could not combine data to generate a summary e ects estimate.
Quality of the evidence
We assessed the quality of the evidence using the GRADE approach (Jüni 2001), and reported the outcomes in a 'Summary of findings' table (Summary of findings for the main comparison).
For time to resolution of pleural e usion, we combined data on residual pleural fluid on chest X-ray from four trials. As described in the results section, a er exploring high unexplained statistical heterogeneity for this outcome, we chose to exclude the two trials that were at high risk of selection bias from the final analysis to avoid a misleading summary estimate of e ect. The exclusion of studies from the meta analysis generates uncertainty, and therefore we chose to downgrade by one because of this. We also downgraded for imprecision; the number of participants and events is small, the meta analysis is probably underpowered.
We graded the summary e ects estimate for pleural changes at the end of treatment as low certainty evidence, and downgraded due to concerns about risk of bias relating to randomization and allocation methods, and for imprecision relating to the relatively small number of events and participants.
For long-term functional respiratory impairment, we graded the quality of the evidence as very low. Meta-analysis was not possible for this outcome due to insu icient reporting of data, and we reported the available data in Table 7 . Although two trials reported the mean percentage predicted forced vital capacity (FVC) at the end of treatment (Galarza 1995 , Wyser 1996 , neither the results per participant nor the variance were reported.
For adverse events leading to discontinuation of the trial drug, we assessed the quality of the evidence as low. We downgraded for risk of bias relating to randomization and allocation concealment, and also reporting as some trials did not report on adverse events in detail. Also a few only referred to adverse e ects associated with steroids in the steroid group, which raised the concern that adverse events in the control group were not detected or reported.
For adverse events relating to HIV, we graded the estimates of e ect relating to two serious, life-threatening HIV-related diseases -cryptococcal meningitis and Kaposi's sarcoma -and judged the quality of the evidence to be very low. We downgraded by two for imprecision caused by the small number of events and participants, and also by one for indirectness as the participants were all from one single-centre trial and none were on antiretroviral therapy. These estimates of e ect may not be applicable to HIV-positive people in other settings or those taking antiretroviral therapy.
Potential biases in the review process
We attempted to limit bias in the review process. Vittoria Lutje, the Cochrane Infectious Diseases Group Information Specialist, conducted the literature searches, and it is unlikely that these searches missed any major trials; however, we cannot rule out the possibility that we missed some small unpublished trials. The funnel plot did not assist with this because there were too few included trials. To limit bias in the trial selection process and data extraction, we independently examined the search results, determined study selection, and extracted data.
Agreements and disagreements with other studies or reviews
There are relatively few studies and reviews on this topic in the literature. We could find no other systematic reviews that address this question. Chapman 2004, a narrative review of the diagnosis and management of pleural space infection, comments that the role of steroids is uncertain as study findings are conflicting, and do not provide information about the e ect of steroids on longterm lung function and mortality. Another narrative review, Ferreiro 2014, drew similar conclusions, and noted that the conflicting results between studies and the possibility raised by Elliott 2004 that use of corticosteroids in HIV-positive patients with TB pleurisy may lead to increased risk of Kaposi's sarcoma. Kadhiravan 2010 commented on the previous version of this review (Engel 2007) , and noted that while there appears to be an e ect of corticosteroids on pleural thickening, the available evidence does not show an e ect on lung function.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The included trials in this review do not provide substantive evidence on patient-important outcomes to guide recommendations on the use of corticosteroids in people with Cochrane Database of Systematic Reviews TB pleurisy. The e icacy of corticosteroids in reducing the time to resolution of pleural e usion or symptoms is uncertain, although the included trials that were at low risk of bias did demonstrate more rapid resolution of pleural e usion on chest X-ray in participants treated with corticosteroids. There may be a decreased risk of pleural changes such as pleural thickening and pleural adhesions on chest X-ray at the end of treatment with corticosteroids, but it is unclear how this relates to patient-important outcomes such as disability, lung function, and mortality. The concerns raised regarding adverse events in both HIV-negative and HIV-positive people with pleural TB need to be taken into account when deciding whether or not to use corticosteroids.
Current guidelines for TB treatment do not recommend the use of corticosteroids in pleural TB (INDEX-TB 2016; NICE 2016; WHO 2010) .
Implications for research
The literature search performed for this update revealed no new trials that compared corticosteroids to placebo in people with pleural TB, and no trials are ongoing at the time of publication of this Cochrane Review. We prepared a rapid update of this review as part of the development process of guidelines on extrapulmonary TB in India, the INDEX-TB Guidelines (INDEX-TB 2016) . During discussions regarding the use of corticosteroids for pleural TB, the guideline panel noted that, as pleural TB is generally associated with low mortality, the priority outcome for consideration is lung function. The panel felt that the main outcomes in the available studies are at best proxy measures for lung function, and, given the evidence for adverse e ects of corticosteroids, made a conditional recommendation against their use in pleural TB.
It is notable that the two trials included in this review that do report on lung function suggest that, while there was no qualitative di erence between the two treatment groups, many people who have been successfully treated for pleural TB have poorer than expected lung function. There are still questions to be answered regarding lung function, disability, and mortality a er pleural TB.
A systematic review of studies that investigated the prevalence of chronic lung disease in general populations concluded that pulmonary TB is strongly associated with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and bronchiectasis (Byrne 2015) . Two studies included in the review showed a stronger association between pulmonary TB and chronic lung disease in non-smokers than in smokers, which suggested that the relationship is not due to confounding risk factors alone. Indeed, the association between pulmonary TB and chronic lung disease has been recognized for many decades. More recently the interconnected causal relationships between TB, HIV, smoking, and chronic lung disease have been further elucidated, although many questions regarding pathophysiology remain unanswered (van Zyl Smit 2010). There is less evidence regarding the association between pleural TB and chronic lung disease or respiratory impairment. Candela 2003 reported on functional sequelae in terms of pulmonary function testing in a cohort of 81 Spanish adults with pleural TB with a median follow-up time of 23 months a er diagnosis. Investigators found that 8/81 (10%) of the participants had a restrictive ventilatory deficit (one or both of FVC and TLC < 80% of predicted, with a FEV 1 /FVC ratio > 80% of predicted) at the end of follow-up, which they describe as mild to moderate in all but two cases who were both smokers with a pre-existing diagnosis of COPD. They found no statistically significant association between residual pleural thickening on chest X-ray and functional sequelae at end of follow-up, although the sample was too small to rule out an association. They also found that the pleural fluid profile of participants that went on to have a restrictive ventilatory deficit demonstrated lower levels of lactate dehydrogenase and higher lymphocyte count, suggesting a di erence in the inflammatory response in the pleural space. Their results provide context to the results of this review: if there is poor correlation between pleural thickening on chest X-ray and functional sequelae, we cannot conclude that if corticosteroids reduce pleural thickening they are likely to be of benefit in terms reducing rates of lung function impairment.
Given the uncertainties that exist, further research is warranted to explore the relevance of discriminating between people presenting with isolated pleural TB and pleuro-pulmonary TB, using di erent imaging modalities such as computed tomography and ultrasound. Cohort studies are needed in people who have pleural TB of either type to assess the incidence of functional sequelae, as measured using spirometry and also disability metrics validated for disability related to impaired lung function. The utility of further randomized controlled trials for corticosteroids in pleural TB would be informed by the results of such research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Methods
Setting: Inha University Hospital, South Korea
Date: recruitment from June 1991 to September 1994
Trial design: prospective randomized study Follow-up: duration not clearly reported, 8 to 9 months. Chest X-rays were performed weekly while participants were hospitalized, then monthly after discharge. Participants were asked to complete a questionnaire detailing their symptoms every day until resolution of all symptoms.
Participants
Number of participants: 84 adults (83 included in analysis, 1 participant was excluded because they experienced increased epigastric pain after commencing steroids and so study drug was stopped); 49 male (59%), 34 female (41%)
Age: mean 34 years, range 18 to 50 years Inclusion criteria: patients who were admitted to the hospital and diagnosed with tuberculous pleurisy. All participants had pleural biopsy and diagnostic pleurocentesis performed on the 1st or 2nd day of admission. Diagnosis of tuberculosis (TB) pleurisy was based upon the following: histological findings corresponding to TB on pleural biopsy, acid-fast bacilli (AFB) positive on smear microscopy or culture positive from sputum, pleural fluid, or pleural biopsy.
Exclusion criteria
• People with pleural effusion caused by congestive heart failure, pneumonia, or malignancy • People with diabetes, hypertension, and peptic ulcer disease who could not be treated with corticosteroids HIV status: all participants were HIV-negative. The trial took place during a period when HIV infection was very uncommon in South Korea.
Interventions
Intervention: ATT plus prednisolone 1 mg/kg twice daily, tapered by 10 mg each week until complete cessation Cochrane Database of Systematic Reviews ATT: isoniazid (400 mg/day), rifampicin (600 mg/day; 450 mg if weight 50 kg or less), pyrazinamide (1500 mg/day), ethambutol (800 mg/day) for 2 months followed by same regimen minus pyrazinamide for 7 months Outcomes • Mean duration to relief from symptoms, as assessed by a self-reporting questionnaire asking about presence or absence of sensation of fever, chest pain, cough, sputum production, shortness of breath, night sweats, weight loss, and fatigue • Rate of reabsorption of pleural fluid • Pleural adhesions and thickening
Control: ATT alone
Notes
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
High risk
The trial authors did not state the method of randomization, and the number of participants in each group appears imbalanced (steroid group N = 34, control group N = 50).
"Patients deemed eligible for this study were randomized to the steroid group and the non-steroid group."
Allocation concealment (selection bias)
Unclear risk
The trial authors did not report this information.
Blinding of participants and personnel (performance bias) All outcomes
Blinding of outcome assessment (detection bias) All outcomes
Incomplete outcome data (attrition bias) All outcomes
Low risk
No losses to follow-up were reported.
Selective reporting (reporting bias)
The trial protocol was unavailable, but the trial authors reported all outcomes specified in the introduction in the results.
Other bias Low risk
We did not identify any other sources of bias.
Bang 1997 (Continued) Trial design: randomized, doubled-blind, placebo-controlled trial Follow-up: all participants were followed up until July 2002; median follow-up time was 1.48 years in the steroid group, and 1.65 years in the placebo group. Participants were managed in hospital or as daily ward attenders for the first week of treatment, and after that were discharged home and visited regularly to monitor treatment for 8 weeks. Participants then attended clinic monthly until the end of ATT, and then 3-monthly after ATT completion. Exclusion criteria: people recently treated with glucocorticoids, pregnant, or breast-feeding women, and people not resident in Kampala were excluded from screening. The trial excluded people after screening if they failed to completed the screening procedures, pleural fluid could not be obtained, they had empyema, they had a second major HIV-related disease, they had risk factors for serious steroid-related adverse events (history of diabetes or finding of glycosuria, history or finding of hypertension, history of peptic ulcer disease, or mental illness), they could not receive standard doses of antituberculous treatment (ATT) (for example, concurrent liver disease), they were HIV-negative.
HIV status: the trial excluded HIV-negative people
Interventions
Intervention: ATT plus prednisolone 50 mg daily for 2 weeks, then 40 mg daily for 2 weeks, then 25 mg daily for 2 weeks, then 15 mg daily for 2 weeks, then stopped.
Control: ATT plus placebo. ATT: daily rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by daily rifampicin and isoniazid for 4 months; doses adjusted for weight using standard criteria.
Outcomes
• All-cause mortality • Time to resolution of anorexia, cough, and pleural effusion • Weight • CD4 count and viral load • Adverse events related to steroid use • Adverse events related to HIV
Notes
The trial authors did not mention antiretroviral therapy in this trial. We contacted the trial authors to check whether any of the participants were given antiretroviral therapy, and they reported that to the best of their knowledge none of the participants were taking antiretroviral therapy at any time during the trial.
Risk of bias
Bias Authors' judgement Support for judgement
Low risk "The randomization sequence was generated by a statistician who was not involved in the care of the patients, by use of STATA (version 5; Stata Corporation). Randomization was done in blocks of 20."
Allocation concealment (selection bias)
Low risk "Prednisolone and matching placebo tablets were packaged in identical plastic bags, which were labeled with randomization code numbers by two people who were not involved in the study. Medical sta gave participants the next number in the sequence in the order in which they were enrolled."
Blinding of participants and personnel (performance bias)
Low risk "All participants and medical, laboratory, and statistical sta remained blinded to the treatment allocation until all data collection had been completed." 
Cochrane Database of Systematic Reviews
All outcomes
Low risk "All participants and medical, laboratory, and statistical sta remained blinded to the treatment allocation until all data collection had been completed."
Low risk Nine participants were lost to follow-up, 6/98 in the steroid group and 3/99 in the placebo group, representing 5% of the total participants.
High risk
The study protocol was not available. The primary outcome was all-cause mortality and this is clearly stated, but the other outcomes are not specified in the introduction or methods section.
"The use of prednisolone was associated with more-rapid improvement in all of the principal symptoms and signs of pleural tuberculosis. This effect was statistically significant, particularly during the first few weeks of treatment, for anorexia, weight loss, and cough ( figure 3A-C) ." Only data related to the statistically significant outcomes for symptomatic improvement are reported.
Other bias Low risk
We did not identify any other potential sources of bias.
Elliott 2004 (Continued) 
Cochrane Database of Systematic Reviews
Standard regimen: isoniazid (5 mg/kg/day; max 300 mg/day); rifampicin (10 mg/kg/day; max 600 mg/ day); once daily as a combination tablet for 6 months Outcomes • Time to resolution of fever • Lung function assessed by forced vital capacity (FVC) at end of treatment • Pleural thickening at baseline and at 1, 6, and 12 months after start of treatment • Rate of reabsorption of pleural fluid on chest x-ray at baseline and at 1, 6, and 12 months after start of treatment • Adverse effects
Notes
A definite microbiological or pathological diagnosis was confirmed in 63% of participants.
Before discharge, pleural fluid was drained until 1/3 of hemithorax was occupied on standard chest Xray in all participants.
Risk of bias
Bias Authors' judgement Support for judgement
Unclear risk
The trial authors did not describe the method of randomization.
Allocation concealment (selection bias)
Unclear risk
The trial authors did not describe the method of allocation concealment.
Low risk "Patients were randomly assigned to receive, in a double blind fashion, either prednisolone or placebo".
The trial authors did not mention the blinding of outcome assessors.
Low risk
The trial authors did not report any losses to follow-up; there were no unexplained defaulters.
Low risk No protocol available, but the trial authors reported on the 2 main outcomes specified in the introduction.
Other bias Low risk
We did not identify any other source of bias.
Galarza 1995 (Continued) Criteria for tapering prednisolone dose as follows
• Right-sided effusion with fluid level only one intercostal space higher than the le hemidiaphragm • Le -sided effusion with fluid level at the same height as the right hemidiaphragm • Complete resolution of the effusion
Risk of bias
Bias Authors' judgement Support for judgement
Unclear risk "Those who were eligible for the study were randomly assigned to treatment with either prednisolone plus antituberculosis drugs (steroid group) or placebo with antituberculosis drugs (placebo group."
Allocation concealment (selection bias)
Unclear risk The trial authors did not describe the method of allocation concealment.
Blinding of participants and personnel (performance bias) All outcomes
Low risk The trial authors described this as "double blind".
Unclear risk
The trial authors did not mention whether blinding of outcome assessors took place or not.
Incomplete outcome data (attrition bias) All outcomes
High risk The trial excluded 5 participants excluded from the final analysis; 1 due to diagnosis of renal cell carcinoma and 4 due to loss to follow-up with no further information given. Therefore the trial authors included 89% of recruited participants in the final analysis. The trial authors did not report which groups the five excluded participants were randomized to. 
Cochrane Database of Systematic Reviews
Low risk
There was no protocol available, but the trial authors reported all outcomes that they clearly stated in the methods.
Other bias Low risk
Lee 1988 (Continued) Methods Setting: Chung-Ang University Hospital, South Korea Date: February 1990 to February 1997
Trial design: prospective randomized study Follow-up: participants were followed up at 2 months and 6 months, and in a final visit to the out-patient department after treatment. Median follow-up was 9 months in the steroid group and 12 months in the control group. Exclusion criteria: people with pleural effusion due to other causes (not specified by the trial authors). People with diabetes, hypertension, or peptic ulcer disease who could not receive corticosteroids. People who were "not cooperative".
Participants
HIV status: not mentioned.
Interventions
Intervention: ATT plus prednisolone 30 mg once daily for 1 month and then tapered over the following month. Control: ATT alone. ATT regimen: isoniazid, rifampicin, pyrazinamide, and ethambutol for 6 months or isoniazid, rifampicin, pyrazinamide, and streptomycin for 2 months followed by same regimen minus streptomycin for 4 months; dosage not stated Outcomes • Time to resolution of pleural effusion • Development of pleural adhesions, defined as lack of resolution of pleural effusion on chest x-ray up to final visit
Notes
Risk of bias
Bias Authors' judgement Support for judgement
High risk
The trial did not state the method of randomization, and the number of participants in each group appears imbalanced (steroid group N = 50, control group N = 32). "… patients were randomized to the steroid group and the non-steroid group".
Allocation concealment (selection bias)
Unclear risk The trial authors did not report on the method of allocation concealment. 
Cochrane Database of Systematic Reviews
Unclear risk
The trial authors did not report on blinding of participants and personnel.
The trial did not report on blinding of outcome assessment.
Incomplete outcome data (attrition bias) All outcomes
Low risk There were no losses to follow-up.
Low risk
Other bias Low risk
Lee 1999 (Continued) The trial authors excluded 4 participants from analysis, 3 due to non-compliance with treatment, 1 due to diagnosis of oesophageal cancer at follow-up. The trial authors did not report to which group the excluded participants were randomized to.
Age: mean age 33 years
Inclusion criteria: pleural biopsy specimen proving TB pleurisy, based on presence of caseating granulomata with or without AFB on histological examination, or a positive culture for M. tuberculosis.
Diagnostic algorithm: thoracoscopy followed by bronchoscopy under general anaesthesia, with biopsies of the parietal pleura taken for histological examination and culture. 
Risk of bias
Bias Authors' judgement Support for judgement
Unclear risk "All eligible patients were randomly assigned in a double-blind fashion to treatment with either prednisone plus standard anti-TB therapy (prednisone group) or placebo plus standard anti-TB therapy (placebo group)."
Unclear risk
The trial described the placebo tablets as "identical". The trial authors did not clearly describe the method of concealment.
Low risk
The trial authors described the trial as "double blind".
The outcome assessors were "blinded to the clinical history".
Unclear risk
The trial authors excluded four participants from the analysis; 3 due to "noncompliance with the treatment".
Low risk
The protocol was unavailable, but the trial authors reported the outcomes described in the introduction.
Other bias Low risk
We did not identify any other source of bias. Cochrane Database of Systematic Reviews • Chest X-ray • Unspecified diagnostic tests to exclude heart failure, malignancy, pneumonia, diabetes mellitus • Chest ultrasound or CT scan in participants with persisting pleural effusion after 3 months Lee 1999 TB on pleural biopsy, or pleural effusion plus AFB stain positive or culture positive from sputum, pleural fluid, or pleural biopsy
Characteristics of ongoing studies [ordered by study ID]
D A T A A N D A N A L Y S E S Comparison 1. Corticosteroids versus control (placebo or no steroids)
• Chest X-ray Wyser 1996 Pleural biopsy with caseating granulomata with or without AFB on histological examination, or positive culture.
• Chest X-ray • Unspecified tests to rule out pneumonia, empyema, malignancy, diabetes mellitus • HIV test • Thoracoscopy and bronchoscopy performed under general anaesthesia • High-resolution CT chest at three levels to measure pleural thickness • Spirometry and body plethysmography Table 3 
. Diagnostic testing in included trials
Abbreviations: ADA: adenosine deaminase activity; AFB: acid-fast bacilli; CT: computed tomography; ELISA: enzyme-linked immunosorbent assay; FEV 1 : forced expiratory volume at one second; FVC: forced vital capacity; HIV: human immunodeficiency virus; PPD: purified protein derivative; PPD-S: purified protein derivative-standard; TB: tuberculosis
Trial
Steroid Regimen . Time to resolution of pleural e usion on chest X-ray (Continued) Abbreviations: N: number of participants 1 Reabsorption index = (length of a ected hemithorax/length of healthy hemithorax) x 100. 2 P = 0.01. 3 Data at this time point extrapolated from graph. Data for 4 weeks and 8 weeks from the trial authors (unpublished data). Table 7 . Pulmonary function at the end of treatment Abbreviations: FVC: forced vital capacity; N: number of participants; PFT: pulmonary function tests 1 Range 65% to 130% in steroid group, 63% to 140% in placebo group. 2 Read from graph, P = 0.65. 3 P = 0.72. Results extrapolated from percentages.
Trial Corticosteroid Control
Bang 1997 1/34 (2.9%) 1 0/50 Table 8 . Adverse events leading to discontinuation of the trial drug (Continued) Abbreviations: NR: not reported 1 Aggravation of epigastric pain in one patient, steroids stopped, and patient withdrawn from the trial. 2 Trial drug discontinued for hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants), oesophageal candidiasis (one participant) in the corticosteroid group; in the placebo group hyperglycaemia (one participant) and hypertension (one participant). 3 One participant developed moon facies, epigastric pain, and lower limb oedema, all of which resolved on tapering the dosage. 4 Epigastric pain was the only adverse e ect noted, and a ected four participants in the steroid group and three in the control group. 
